- Home
- INSM vs SEATW Comparison
INSM vs SEATW Comparison
Compare INSM & SEATW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSM
- SEATW
- Stock Information
- Founded
- INSM 1988
- SEATW N/A
- Country
- INSM United States
- SEATW United States
- Employees
- INSM N/A
- SEATW 768
- Industry
- INSM Biotechnology: Pharmaceutical Preparations
- SEATW Industrial Machinery/Components
- Sector
- INSM Health Care
- SEATW Industrials
- Exchange
- INSM Nasdaq
- SEATW Nasdaq
- Market Cap
- INSM 13.7B
- SEATW N/A
- IPO Year
- INSM 2000
- SEATW N/A
- Fundamental
- Price
- INSM $81.01
- SEATW $0.40
- Analyst Decision
- INSM Strong Buy
- SEATW
- Analyst Count
- INSM 16
- SEATW 0
- Target Price
- INSM $84.29
- SEATW N/A
- AVG Volume (30 Days)
- INSM 2.0M
- SEATW N/A
- Earning Date
- INSM 02-20-2025
- SEATW N/A
- Dividend Yield
- INSM N/A
- SEATW N/A
- EPS Growth
- INSM N/A
- SEATW N/A
- EPS
- INSM N/A
- SEATW N/A
- Revenue
- INSM $342,958,000.00
- SEATW N/A
- Revenue This Year
- INSM $19.74
- SEATW N/A
- Revenue Next Year
- INSM $43.16
- SEATW N/A
- P/E Ratio
- INSM N/A
- SEATW N/A
- Revenue Growth
- INSM 22.13
- SEATW N/A
- 52 Week Low
- INSM $21.92
- SEATW N/A
- 52 Week High
- INSM $81.25
- SEATW N/A
- Technical
- Relative Strength Index (RSI)
- INSM 68.75
- SEATW 55.87
- Support Level
- INSM $74.47
- SEATW $0.35
- Resistance Level
- INSM $80.63
- SEATW $0.44
- Average True Range (ATR)
- INSM 2.98
- SEATW 0.03
- MACD
- INSM 0.55
- SEATW -0.01
- Stochastic Oscillator
- INSM 98.08
- SEATW 85.56
About INSM Insmed Incorporated
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
About SEATW Vivid Seats Inc. Warrant
Vivid Seats Inc is an online ticket marketplace for connecting fans to live events and artists. It is the official ticketing partner of brands in the entertainment industry providing tickets for sports, concerts, theatres, and comedy events in the United States, Canada and Japan. It operates in two segments namely marketplace and resale.